Liggett S B
Department of Medicine, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA.
Pharmacology. 2000 Sep;61(3):167-73. doi: 10.1159/000028397.
beta(1)- and beta(2)-adrenergic receptors are G protein-coupled receptors expressed throughout the body and serve as receptors for the catecholamines epinephrine and norepinephrine. They are targets for therapeutive agonists and/or antagonists in treatment of heart failure and asthma. Nonsynonymous coding and promoter polymorphisms of both receptors have been identified in the general population. These have been mimicked in transfected cell systems and transgenic mice, and show altered expression, ligand binding, coupling, or regulation phenotypes. Clinical studies to date have revealed that some of these polymorphisms have a significant disease modifying effect or alter the response to treatment. These are some of the first G protein coupled receptor polymorphisms to undergo extensive in vitro study and clinical validation; there are likely to be polymorphisms of other receptors of the superfamily that will have clinical relevance as well.
β1和β2肾上腺素能受体是在全身表达的G蛋白偶联受体,作为儿茶酚胺肾上腺素和去甲肾上腺素的受体。它们是治疗心力衰竭和哮喘的治疗性激动剂和/或拮抗剂的作用靶点。在普通人群中已鉴定出这两种受体的非同义编码和启动子多态性。这些多态性已在转染细胞系统和转基因小鼠中得到模拟,并表现出表达、配体结合、偶联或调节表型的改变。迄今为止的临床研究表明,其中一些多态性具有显著的疾病修饰作用或改变治疗反应。这些是首批接受广泛体外研究和临床验证的G蛋白偶联受体多态性;超家族的其他受体可能也存在具有临床相关性的多态性。